Reach Us +44-7482-864460
Impact Of A Moderate-fat Meal On The Bioavailability Of Ribavirin In Patients With Hepatitis C | 85191
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Share This Page

Impact of a moderate-fat meal on the bioavailability of Ribavirin in patients with hepatitis C

Joint Meeting on 4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics

Sara Ibrahim Altraif, Shazia Murtaza, Pierre Marquet, Abdulkareem Albekairy, Faisal M Sanai, Hamdan Alghamdi, Abduljaleel Alalwan, Abdulrahman Aljumah, Mohammed Hussein, Naila Shaheen, Altaf Khan and Ibrahim Altraif

King Abdulaziz Medical City, Saudi Arabia

Posters & Accepted Abstracts: J Mol Genet Med

DOI: 10.4172/1747-0862-C1-025

Ribavirin is a nucleoside analog used in hepatitis C therapy. The bioavailability of oral Ribavirin is increased by coadministration with high-fat food. Therefore, Ribavirin manufacturers recommend taking the drug with food. However, moderate fat meal effect on Ribavirin bioavailability is yet not established. Our objectives were to compare the bioavailability of Ribavirin in patients with hepatitis C virus (HCV) genotype 4 (G4), either taken after a moderate-fat meal or in fasting state. We conducted a crossover, randomized, open-label study including 82 naïve patients (49 women and 33 men, mean age 53.40±1.39 years) with chronic hepatitis C at King Abdulaziz Medical City, Riyadh, Saudi Arabia, from 2012 to 2014. Patients received 600 mg of oral Ribavirin on two occasions at least three weeks apart of washout period: first in a fasting state and second time after a moderate fat breakfast containing X18 g fat. Participants in both states underwent a pharmacokinetic profile analysis at 0.5, 1.0 and 2.0 hours after each dose. Compared with the fed state, Ribavirin plasma concentrations were significantly higher in the fasting state at 0.5 hours and 1 hour post-dose (p=0.004 and 0.021, respectively) and significantly lower at 2 hours post-dose (p=0.011). However, the area under the curve for Ribavirin concentrations within the first 4 hours post-dose (AUC0-4h) was not different between the two states (p=0.956). Among adult patients with HCV G4, there was no significant difference in Ribavirin bioavailability between fasting and fed (X18 gram fat meal) states, thus for better adherence we recommend that physicians consider patient convenience in regards to the timing of Ribavirin oral intake. [email protected]